These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The effect of food and time of administration on the pharmacokinetic and pharmacodynamic profile of metrifonate. Heinig R, Sachse R. Int J Clin Pharmacol Ther; 1999 Sep; 37(9):456-64. PubMed ID: 10507245 [Abstract] [Full Text] [Related]
17. Metrifonate therapy in Alzheimer's disease: a pooled analysis of four randomized, double-blind, placebo-controlled trials. Farlow MR, Cyrus PA. Dement Geriatr Cogn Disord; 2000 Jan; 11(4):202-11. PubMed ID: 10867446 [Abstract] [Full Text] [Related]
18. Effects of metrifonate, its transformation product dichlorvos, and other organophosphorus and reference cholinesterase inhibitors on Morris water escape behavior in young-adult rats. van der Staay FJ, Hinz VC, Schmidt BH. J Pharmacol Exp Ther; 1996 Aug; 278(2):697-708. PubMed ID: 8768721 [Abstract] [Full Text] [Related]
19. Metrifonate: update on a new antidementia agent. Ringman JM, Cummings JL. J Clin Psychiatry; 1999 Nov; 60(11):776-82. PubMed ID: 10584768 [Abstract] [Full Text] [Related]
20. The recovery of cerebrospinal fluid acetylcholinesterase activity in Alzheimer's disease patients after treatment with metrifonate. Unni L, Vicari S, Moriearty P, Schaefer F, Becker R. Methods Find Exp Clin Pharmacol; 2000 Nov; 22(1):57-61. PubMed ID: 10791297 [Abstract] [Full Text] [Related] Page: [Next] [New Search]